Form 4: Plus Therapeutics CEO Vesting Event

Marc Hedrick, CEO of Plus Therapeutics, reports on the vesting of Restricted Stock Units (RSUs) on July 1, 2026, increasing his beneficial ownership of common stock.

Summary

• Marc Hedrick, Chief Executive Officer and Director of Plus Therapeutics, Inc. (PSTV), reported a transaction on July 1, 2026.
• This transaction involved the vesting of Restricted Stock Units (RSUs), which represent a contingent right to receive shares of the company's common stock.
• Specifically, 6,387 RSUs vested, increasing his direct beneficial ownership of common stock to 34,431 shares.
• An additional 8,066 RSUs vested, bringing his total direct beneficial ownership to 42,497 shares.
• Furthermore, 1,986 RSUs vested, resulting in a total direct beneficial ownership of 44,483 shares.
• These RSUs vest in twelve substantially equal quarterly installments, with specific start dates for each grant: October 1, 2025, April 1, 2026, and July 1, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents the routine vesting of previously granted equity awards rather than a new strategic development or financial performance indicator.

Positives

• The vesting of RSUs indicates continued commitment and potential long-term alignment of management with shareholder interests.
• The CEO's beneficial ownership of common stock has increased, reflecting the conversion of equity awards into actual shares.

Negatives

• The filing details the vesting of previously granted equity awards, not new acquisitions of stock through purchase, which could be seen as a non-cash event for the executive.

Risks

• The vesting schedule for RSUs is tied to quarterly installments, meaning the full benefit is realized over time, not immediately.
• The value of the vested shares is subject to market fluctuations and the company's stock performance.

Future Outlook

The filing details the vesting of existing equity awards and does not contain forward-looking financial guidance or projections.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, such as the vesting of equity awards, which are common in the biotechnology and pharmaceutical sectors as a method of executive compensation and retention.

Stakeholder Impact

• Shareholders: The increase in the CEO's beneficial ownership through RSU vesting can be seen as a positive signal of management's long-term commitment, though it does not represent new capital invested.
• Employees: The vesting of RSUs is part of the executive compensation structure and does not directly impact other employees.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued vesting of RSU grants according to the specified quarterly schedules.

Key Dates

Keywords

Form 4, SEC Filing, Plus Therapeutics, PSTV, Marc Hedrick, Restricted Stock Units, RSU Vesting, Beneficial Ownership, Insider Transaction, Executive Compensation